Holen Sie sich die Stockscreener-App
141.96
0.87%
-1.25
Handel nachbörslich:
141.96
Schlusskurs vom Vortag:
$143.21
Offen:
$142.62
24-Stunden-Volumen:
764.18K
Relative Volume:
0.87
Marktkapitalisierung:
$14.08B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
48.12
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
-4.69%
1M Leistung:
+3.60%
6M Leistung:
+29.43%
1J Leistung:
+16.16%
1-Tages-Spanne:
$139.46
$144.98
1-Wochen-Bereich:
$133.61
$149.98
52-Wochen-Spanne:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
141.96 | 14.28B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
How Neurocrine Biosciences Inc. stock responds to policy changesJuly 2025 Gainers & Long-Term Safe Investment Ideas - newser.com
Neurocrine taps China biotech for NLRP3 programs: Deals Report - BioCentury
Key facts: JP Morgan Raises Neurocrine Target to $179; TransThera Deal Worth $881.5M - TradingView
Neurocrine Bio. stock price target raised to $147 by BMO Capital - Investing.com Canada
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends further2025 Price Momentum & Scalable Portfolio Growth Methods - newser.com
What data driven models say about Neurocrine Biosciences Inc.’s futureWeekly Stock Report & Daily Oversold Bounce Ideas - newser.com
Applying sector rotation models to Neurocrine Biosciences Inc.Market Volume Report & Risk Adjusted Swing Trade Ideas - newser.com
Measuring Neurocrine Biosciences Inc.’s beta against major indicesWeekly Investment Recap & Smart Money Movement Tracker - newser.com
Why Neurocrine Biosciences Inc. stock remains resilientJuly 2025 Movers & Safe Capital Growth Trade Ideas - newser.com
How big funds are accumulating Neurocrine Biosciences Inc. (NB3) stockJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyMarket Risk Analysis & High Return Stock Watch Alerts - newser.com
Neurocrine Biosciences (NBIX): Assessing Valuation After Strong Q3 Results and Pipeline Progress - simplywall.st
Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikes2025 Buyback Activity & AI Enhanced Trading Alerts - newser.com
Can Neurocrine Biosciences Inc. stock weather global recession2025 Trade Ideas & Stock Portfolio Risk Management - newser.com
What earnings revisions data tells us about Neurocrine Biosciences Inc.Market Movers & Daily Volume Surge Trade Alerts - newser.com
Can Neurocrine Biosciences Inc. stock sustain revenue growth2025 Volume Leaders & AI Powered Trade Plan Recommendations - newser.com
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockVolume Spike & AI Driven Stock Reports - newser.com
What moving averages say about Neurocrine Biosciences Inc.Portfolio Performance Report & Accurate Buy Signal Alerts - newser.com
TransThera Sciences Sells NLRP3 Inhibitor License to Neurocrine Bioscience - MarketScreener
Transthera Sciences (Nanjing) Inc Announces Collaboration With Neurocrine Biosciences Inc For NLRP3 Inhibitors - TradingView
TransThera Sciences Partners with Neurocrine for NLRP3 Inhibitors Development - TipRanks
How risky is Neurocrine Biosciences Inc. stock nowEarnings Miss & Real-Time Volume Trigger Notifications - newser.com
1,945 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Daymark Wealth Partners LLC - MarketBeat
What analysts say about Neurocrine Biosciences Inc stockMarket Timing Techniques & Explosive Trading Portfolio - earlytimes.in
Is It Time to Lock in Profits on Winsol Engineers Limited StockPrice Volatility Patterns & Exceptional Trading Strategies - earlytimes.in
Cantor Fitzgerald Brokers Raise Earnings Estimates for NBIX - MarketBeat
Brighton Jones LLC Invests $351,000 in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Short interest data insights for Neurocrine Biosciences Inc.Trade Analysis Report & Long-Term Safe Investment Plans - newser.com
Neurocrine Biosciences (NASDAQ:NBIX) Given Buy Rating at Truist Financial - MarketBeat
Will Neurocrine Biosciences Inc. (NB3) stock return to pre crash levels2025 Price Targets & AI Optimized Trading Strategy Guides - newser.com
Is it time to cut losses on Neurocrine Biosciences Inc.2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Jennison Associates LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
What analysts say about Neurocrine Biosciences Inc NB3 stockHealthcare Stock Analysis & Minimal Capital Trading Tips - earlytimes.in
Is The Indian Link Chain Manufactures Limited a Growth Buy or Value Trap This YearFundamental Strength Indicators & Free Daily Stock Hotspot Analysis - earlytimes.in
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
2.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):